National Institutes of Health to Grant Exclusive License for Cancer Treatment Patent

Summary

The National Institutes of Health is considering granting an exclusive worldwide license to NeoPharm, Inc. for the use of a patent for a cancer treatment, specifically the SS(dsFv)-PE38 immunotoxin, for the therapeutic treatment of ovarian cancer and mesotheliomas.